30 closest matches · ranked by relevance
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Lymphoma · Hodgkin Lymphoma (Category) · Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Progression-free Survival (PFS) — 18 participants
Lymphoma
Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Cardiac Toxicity · Chemotherapeutic Agent Toxicity · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Lymphoma
Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV
Hodgkin Disease · Hodgkin's Lymphoma · Lymphoma
Primary: Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity — 0; 3 participants
Lymphoma, Hodgkin Disease · Lymphoma · Hodgkin Disease
Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Hodgkin Disease
Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants
Lymphoma · Hodgkin's Disease
Primary: Disease-free Survival — 76; 88; 70 percentage of participant
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants
Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants
Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Primary: Event-free Survival (EFS) Rate — 17; 20 Participants
Lymphoma
Primary: Overall Response — 3 participants
Lymphoma
Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses
AIDS-Related Hodgkin Lymphoma · Ann Arbor Stage II Hodgkin Lymphoma · Ann Arbor Stage IIA Hodgkin Lymphoma
Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Lymphoma
Primary: Number of Participants With Grade 3-5 Adverse Events — 6 Participants
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Complete Response (CR) Rate — 0; 36 percent of participants
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants